Development of a practical and sustainable strategy for the synthesis of ST1535 by an iron-catalyzed Kumada cross-coupling reaction

Tetrahedron Letters

Volumn 55, Issue 7, 2014, Pages 1376-1378

  Bartoccini, Francesca ^a   Piersanti, Giovanni ^a   Armaroli, Silvia ^b   Cerri, Alberto ^b   Cabri, Walter ^b  

^a UNIVERSITY OF URBINO   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

A 2A receptor antagonist; Cross coupling; Grignard reagent; Iron catalysis; Sustainability

Indexed keywords

ADENOSINE A2A RECEPTOR ANTAGONIST; BORONIC ACID DERIVATIVE; GRIGNARD REAGENT; IRON; MAGNESIUM CHLORIDE; ST 1535; UNCLASSIFIED DRUG;

ARTICLE; CATALYST; CONTROLLED STUDY; CROSS COUPLING REACTION; DRUG SYNTHESIS; KUMADA CROSS COUPLING REACTION; REACTION TIME; SUZUKI REACTION;

EID: 84893737411     PISSN: 00404039     EISSN: 18733581     Source Type: Journal    
DOI: 10.1016/j.tetlet.2014.01.030     Document Type: Article

References (44)

1. E. Negishi Angew. Chem., Int. Ed. 50 2011 6738 6764
2. K.C. Nicolaou, P.G. Bulger, and D. Sarlah Angew. Chem., Int. Ed. 44 2005 4442 4489
3. J. Corbet, and G. Mignani Chem. Rev. 106 2006 2651 2710
4. J. Magano, and J.R. Dunetz Chem. Rev. 111 2011 2177 2250
5. C.C.C. Johansson Seechurn, M.O. Kitching, T.J. Colacot, and V. Snieckus Angew. Chem., Int. Ed. 51 2012 5062 5085
6. R. Jana, T.P. Pathak, and M.S. Sigman Chem. Rev. 111 2011 1417 1492
7. S.D. Roughley, and A.M. Jordan J. Med. Chem. 54 2011 3451 3479
8. J.S. Carey, D. Laffan, C. Thomson, and M.T. Williams Org. Biomol. Chem. 4 2006 2337 2347
9. The world market price of palladium rose in the past five years from 330 to 800 USD/oz: http://palladiumprice.org/palladiumprice-history.html.
10. L. Friberg, G.F. Nordberg, and V.B. Vouk Handbook on the Toxicology of Metals 1986 Elsevier Amsterdam
11. J.J. Hostynek, and H.I. Maibach Nickel and the Skin: Absorption, Immunology, Epidemiology, and Metallurgy 2002 CRC Boca Raton
12. C.E. Garrett, and K. Prasad Adv. Synth. Catal. 346 2004 889 900
13. For reviews on iron-catalyzed cross-coupling reactions, see: W.M. Czaplik, M. Mayer, J. Cvengroš, and A. Jacobi vonWangelin ChemSusChem 2 2009 396 417
14. B.D. Sherry, and A. Fürstner Acc. Chem. Res. 41 2008 1500 1511
15. A. Fürstner, A. Leitner, M. Méndez, and H. Krause J. Am. Chem. Soc. 124 2002 13856 13863
16. For the seminal publication, see: M. Tamura, and J.K. Kochi J. Am. Chem. Soc. 93 1971 1487 1489
17. For general reviews on iron-catalyzed reactions, see: H. Shinokubo, and K. Oshima Eur. J. Org. Chem. 2004 2081 2091
18. A. Correa, O. García Mancheño, and C. Bolm Chem. Soc. Rev. 37 2008 1108 1117
19. B. Plietker Iron Catalysis in Organic Chemistry: Reactions and Applications 2008 Wiley-VCH Weinheim, Germany
20. The presence of nitrogen heterocycles, which are particularly pervasive in medicinal chemistry, too often leads to low reactivity in palladium-catalyzed cross-coupling reactions. This is often caused by binding of the heteroatom in the substrate and product to the metal complex. Although binding is reversible, the large excess of substrate can lead to a strong inhibitory effect. K. Billingsley, and S.L. Buchwald J. Am. Chem. Soc. 129 2007 3358 3366
21. G. Piersanti, F. Bartoccini, S. Lucarini, W. Cabri, M.A. Stasi, T. Riccioni, F. Borsini, G. Tarzia, and P. Minetti J. Med. Chem. 56 2013 5456 5463
22. S. Rivara, G. Piersanti, F. Bartoccini, G. Diamantini, D. Pala, T. Riccioni, M.A. Stasi, W. Cabri, F. Borsini, M. Mor, G. Tarzia, and P. Minetti J. Med. Chem. 56 2013 1247 1261
23. P. Minetti, M.O. Tinti, P. Carminati, M. Castorina, M.A. Di Cesare, S. Di Serio, G. Gallo, O. Ghirardi, F. Giorgi, L. Giorgi, G. Piersanti, F. Bartoccini, and G. Tarzia J. Med. Chem. 48 2005 6887 6896
24. G. Piersanti, L. Giorgi, F. Bartoccini, G. Tarzia, P. Minetti, G. Gallo, F. Giorgi, M. Castorina, O. Ghirardi, and P. Carminati Org. Biomol. Chem. 5 2007 2567 2571
25. For excellent reviews on the field: N. Szaboo, Z.T. Kincses, and L. Veecsei Expert Opin. Drug Metab. Toxicol. 7 2011 441 455
26. J.D. Salamone Drugs Future 35 2010 567
27. B.C. Shook, and P.F. Jackson ACS Chem. Neurosci. 2 2011 555 567
28. F. Bartoccini, W. Cabri, D. Celona, P. Minetti, G. Piersanti, and G. Tarzia J. Org. Chem. 75 2010 5398 5401
29. F. Bartoccini, G. Piersanti, M. Mor, G. Tarzia, P. Minetti, and W. Cabri Org. Biomol. Chem. 10 2012 8860 8867
30. V. Belcastro, A. Tozzi, M. Tantucci, C. Costa, M. Di Filippo, A. Autuori, B. Picconi, S. Siliquini, E. Luchetti, F. Borsini, and P. Calabresi Exp. Neurol. 1 2009 231 245
31. M. Galluzzo, A. Pintor, A. Pezzola, R. Grieco, F. Borsini, and P. Popoli Eur. J. Pharmacol. 579 2008 149 152
32. E. Tronci, N. Simola, F. Borsini, N. Schintu, L. Frau, P. Carminati, and M. Morelli Eur. J. Pharmacol. 566 2007 94 102
33. S. Rose, N. Ramsay Croft, and P. Jenner Brain Res. 1 2007 110 114
34. M.A. Stasi, F. Borsini, K. Varani, F. Vincenzi, M.A. Di Cesare, P. Minetti, O. Ghirardi, and P. Carminati Int. J. Neuropsychopharmacol. 5 2006 575 584
35. For some selected examples: V. Gurram, N. Pottabathini, R. Garlapati, A.B. Chaudhary, B. Patro, and M.K. Lakshman Chem. -Asian J. 7 2012 1853 1861
36. S. Zimdars, X. Mollat du Jourdin, F. Crestey, T. Carrell, and P. Knochel Org. Lett. 13 2011 792 795
37. M. Braendvang, and L.-L. Gundersen Bioorg. Med. Chem. 15 2007 7144 7165
38. N. Vasu, G.A. Turner, G.S. Buenger, and S.D. Chamberlain J. Org. Chem. 53 1988 3051 3057
39. M. Hocek, I. Votruba, and H. Dvořáková Tetrahedron 59 2003 607 611
40. M.C. Bryan, B. Dillon, L.G. Hamann, G.J. Hughes, M.E. Kopach, E.A. Peterson, M. Pourashraf, I. Raheem, P. Richardson, D. Richter, and H.F. Sneddon J. Med. Chem. 56 2013 6007 6021
41. W. Cabri Catal. Today 140 2009 2 10
42. For some limited examples of methylation of dihalopurines using iron catalysts see: M. Hocek, and H. Dvořáková J. Org. Chem. 68 2003 5773 5776
43. M. Hocek, and R. Pohl Synthesis 2004 2869 2876
44. M. Hocek, D. Hocková, and H. Dvořáková Synthesis 2004 889 894